Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease

Movement Disorders

Volumn 12, Issue 4, 1997, Pages 497-505

  Lyytinen, Jukka ^a   Kaakkola, Seppo ^a   Ahtila, Sirpa ^a   Tuomainen, Päivi ^a   Teräväinen, Heikki ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Catecholamines; COMT; Entacapone; MAO B; Parkinson's disease; Selegiline

Indexed keywords

3 O METHYLDOPA; 3,4 DIHYDROXYPHENYLACETIC ACID; 4 HYDROXY 3 METHOXYPHENYLETHYLENE GLYCOL; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; ANTIPARKINSON AGENT; BENSERAZIDE; BENSERAZIDE PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE; CATECHOL METHYLTRANSFERASE INHIBITOR; CATECHOLAMINE; DOPAMINE; ENTACAPONE; HOMOVANILLIC ACID; LEVODOPA; NORADRENALIN; SELEGILINE;

ABDOMINAL PAIN; ADULT; AGED; ANOREXIA; ARTICLE; BLOOD PRESSURE; CATECHOLAMINE BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG TOLERABILITY; ENZYME ACTIVITY; ERYTHROCYTE; FATIGUE; FEMALE; HEADACHE; HUMAN; MALE; NAUSEA; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SLEEP DISORDER; THROMBOCYTE; VERTIGO;

AGED; ANALYSIS OF VARIANCE; ANTIPARKINSON AGENTS; BENSERAZIDE; CATECHOL O-METHYLTRANSFERASE; CATECHOLS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; FEMALE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; MONOAMINE OXIDASE INHIBITORS; MOTOR ACTIVITY; PARKINSON DISEASE; SELEGILINE;

EID: 0030818266     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.870120404     Document Type: Article

References (30)

1. Obeso JA, Grandas F, Vaemorde J. Motor complications associated with chronic levodopa therapy in Parkinson's disease. Neurology 1989;11(suppl 1):11-18.
2. Rinne UK, Lönnberg P, Koskinen V. Dopamine receptor changes in Parkinson's disease. J Neural Transm 1981;51: 97-106.
3. Nutt JG, Fellman JH. Pharmacokinetics of levodopa. Clin Neuropharmacol 1984;7:35-49.
4. Cedarbaum JM. Clinical pharmacokinetics of anti-parkinsonian drugs. Clin Pliarmacokinet 1987;13:141-178.
5. Nissinen E, Linden I-B, Schultz E, Kaakkola S, Männistö PT, Pohto P. Inhibition of catechol-O-methyltransferase activity by two novel disubstituted catechols in the rat. EurJ Pharmacol 1988;153:263-269.
6. Cedarbaum JM, Leger G, Guttman M. Reduction of circulating 3-O-methyldopa by inhibition of catechol-O-methyltransferase with OR-611 and OR-462 in cynomolgus monkeys: implications for the treatment of Parkinson's disease. Clin Neuropharmacol 1991;14:330-342.
7. Jenner P, Smith LA. Interaction of the COMT inhibitor entacapone with L-Dopa in MPTP treated common marmosets [Abstract]. Can J Neural Sci 1993;20:211.
8. Keränen T, Gordin A, Harjola V-P, et al. The effect of catechol-O-methyltransferase inhibition by entacapone on pharmacokinetics and metabolism of levodopa in healthy volunteers. Clin Neuropharmacol 1993;16:145-156.
9. Nutt JG, Woodward WR, Beckner RM, et al. Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology 1994;44:913-919.
10. Kaakkola S, Teräväinen H, Ahtila S, Rita H, Gordin A. Effect of entacapone, a COMT inhibitor, on clinical disability and L-Dopa metabolism in parkinsonian patients. Neurology 1994;44:77-80.
11. Ruottinen HM, Rinne UK. Entacapone prolongs levodopa response in a one month double blind study in parkinsonian patients with levodopa related fluctuations. J Neural Neurosurg Psychiatry 1996;60:36-40.
12. The Parkinson's Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1993;328:176-183.
13. The Parkinson's Study Group. Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1989;321:1364-1371.
14. Tetrud JW, Langston JW. The effect of deprenyl (selegiline) on the natural history of Parkinson's disease. Science 1989; 245:519-522.
15. Golbe LI. Long-term efficacy and safety of deprenyl (selegiline) in advanced Parkinson's disease. Neurology 1989; 39:1109-1111.
16. Myllylä VV, Sotaniemi KA, Illi A, Suominen K, Keränen T. Effect of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson's disease. Eur J Clin Pharmacol 1993;45:419-423.
17. Sundberg S, Scheinin M, Illi A, Akkila J, Gordin A, Keränen T. The effects of the COMT inhibitor entacapone on haemodynamics and peripheral catecholamine metabolism during exercise. Br J Clin Pharmacol 1993;36:451-456.
18. Illi A, Sundberg S, Koulu M, Scheinin M, Heinävaara S, Gordin A. COMT inhibition by high-dose entacapone does not affect hemodynamics but changes catecholamine metabolism in healthy volunteers at rest and during exercise. Int J Clin Pharmacol Ther 1994;11:582-588.
19. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427-442.
20. Fahn S, Elton R, and Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne D, Goldstein M, eds. Recent developments in Parkinson's disease: 2. Florham Park, NJ: Macmillan Healthcare Information, 1987:153-163.
21. Wikberg T. Simultaneous determination of levodopa, its main metabolites and carbidopa in plasma by liquid chromatography. J Pharm Biomed Anal 1991;9:167-176.
22. Karlsson M, Wikberg T. Liquid Chromatographie determination of a new catechol-O-methyltransferase inhibitor, entacapone, and its Z-isomer in human plasma and urine. J Pharm Biomed Anal 1992;10:593-600.
23. Scheinin M, Chang WH, Jimerson DC, Linnoila M. Measurement of 3-methoxy-4-hydroxyphenylglycol in human plasma with high-pressure liquid chromatography using electrochemical detection. Ann Biochem 1983;132:165-170.
24. Gibaldi M, Pcrrier D. Pharmacokinetics. 2nd ed. New York: Marcel Dekker, 1982.
25. Reenilä I, Tuomainen P, Männistö PT. Improved assay of reaction products to quantitate catechol-O-methyltransferase activity by high-performance liquid chromatography with electrochemical detection. J Chromatogr 1995;663:137-142.
26. Freeman KB, Bulawa MC, Zeng Q, Blank CL. Rapid and simultaneous determination of monoamine oxidase A and monoamine oxidase B activities in mouse brain homogenates by liquid chromatography with electrochemical detection. Ann Biochem 1993;208:182-196.
27. Cedarbaum JM, Silvestri M, Clark M, et al. L-Deprenyl, levodopa pharmacokinetics, and response fluctuations in Parkinson's disease, din Neuropharmacol 1990;13:29-35.
28. Hovevey-Sion J, Kopin IJ, Stull RW, Goldstein DS. Effects of monoamine oxidase inhibitors on levels of catechols and homovanillic acid in striatum and plasma. Neuropharmacology 1989;28:791-797.
29. Koulu M, Scheinin M, Kaarttinen A, et al. Inhibition of monoamine oxidase by moclobemide: effects on monoamine metabolism and secretion of anterior pituitary hormones and cortisol in healthy volunteers. Br J Clin Pharmacol 1989;27:243-255.
30. RUSS H, Gerlach M, Dettner O, Kuhn W, Przuntek H. (-)Deprenyl treatment of patients with Parkinson's disease does not affect erythrocyte catechol-O-methyltransferase activity. J Neural Transm 1991;3:215-223.